Did you know that cardiovascular disease (also known as heart disease) is the leading cause of death in Canada? Our very existence relies on the function of the heart. The scary truth is the numbers are ridiculously high when one looks at the prevalence of heart disease. Now, what do we mean when we talk about heart disease? Heart disease encompasses a variety of diseases that affect the heart and/or blood vessels. The most common type is Coronary Heart Disease (CHD) which usually occurs when plaque builds up inside your coronary arteries (i.e. the arteries that supply oxygen-rich blood to your heart) and interferes with blood flow. The length of time the blood flow is shut down will determine the extent of damage to the heart. Insufficient blood supply brings about many severe consequences ranging from chest pain (angina), shortness of breath and finally, heart attack.
It is important to note that the build-up of plaque inside your arteries begins as early as childhood. It is essential to adopt healthy habits early on. Healthy lifestyle works to your advantage not only as a preventive measure but also as a controlling measure. Nevertheless, even for those people who eat healthy, exercise, refrain from smoking and so on, lifestyle changes alone are sometimes not enough when it comes to controlling heart disease. In some cases, medications may just be the key in treating – as well as in easing – some of the pain that accompanies heart disease. Heart attacks are a leading killer of both men and women around the world. The good news is that excellent treatments are available for those at risk. These treatments can save lives and prevent disabilities if planned well ahead.
Speaking of medications, here is some interesting news to lighten up the topic. A biopharmaceutical company, Amarin Corporation plc, will be presenting its data from the MARINE trial later this month. This phase 3 study is investigating AMR10, an omega-3 fatty acid and a potentially best-in-class prescription medicine for the treatment of patients with very high triglyceride levels. In case you didn’t know, elevated levels of triglycerides in the blood have been linked to the risk of developing CHD and are known to play a major role in other metabolic disorders, such as diabetes and obesity.
The CCCT is glad to offer various trials for those affected by heart disease. We are currently recruiting for a new trial evaluating the efficacy of quarterly injections of Canakinumab in the prevention of recurrent cardiovascular events. This investigational medication is specifically for those who had a heart attack in the past. Moreover, we offer trials for type 2 diabetics who happen to be at a high risk for cardiovascular events (medications being investigated: Linagliptin and BI 10773). Previous clinical trials have shown that BI 10773 is effective at reducing blood glucose levels and surprisingly it was associated with 1.5 Kg weight reduction on average. For those of you who are presently suffering from gout as well as have a history of major cardiovascular events, you may want to learn more about a new trial testing the cardiovascular safety of Febuxostat and Allopurinol (both are medications that have been already approved and are now used for the treatment of gout).
For more information or to see if you are eligible for any of our other trials, please click here